Evaluation of a Mobile Application Designed to Support Type 1 Diabetic Patients in Adjusting Thei… (NCT07234500) | Clinical Trial Compass
By InvitationNot Applicable
Evaluation of a Mobile Application Designed to Support Type 1 Diabetic Patients in Adjusting Their Insulin Doses.
Iraq50 participantsStarted 2025-09-01
Plain-language summary
Title: Evaluating a Mobile Application for Insulin Management in Iraqi Type 1 Diabetes Patients.
The goal of this clinical trial is to determine whether a mobile health application can improve insulin management and blood sugar control in Iraqi patients with Type 1 Diabetes aged over 15 years who are on intensive insulin therapy. The main question it aims to answer is:
Does the use of the mobile application lead to a greater reduction in HbA1c levels compared to standard care alone?
Researchers will compare the group using the mobile application to the group receiving standard care alone to see if the application is more effective at improving glycemic control.
Participants will: Be randomly assigned to one of two groups for the 3-month study.
Either use the mobile application to guide their daily insulin dose adjustments alongside standard care, or receive standard care alone.
Undergo blood tests (including HbA1c) and complete questionnaires about hypoglycemic events, insulin adherence, and quality of life.
Who can participate
Age range
15 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
. Patients (≥15 years), with uncontrolled (HbA1c ≥ 7) type 1 diabetes who were treated with multiple daily insulin injections (MDI) for at least 3 months before the study date.
. Patients who are willing to test their blood glucose level at least 3 times daily during the study period.
. Participants who will give their informed consent to participate in the study. -
Exclusion criteria
. Pregnant woman or planning to be pregnant
. Patients at high risk of developing hypoglycemia (e.g., those with IHD, osteoporosis, hypoglycemia unawareness).
. Patients with psychiatric disorders.
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
Change in Glycated Hemoglobin (HbA1c)
Timeframe: Baseline (Day 0) and Post-intervention (Month 3)